MicroRNA expression profiles for diagnosis and microRNA based therapeutics for Alzheimer's disease and related dementias
John F. Crary, M.D., Ph.D..
Could guide development of a highly targeted therapyPotential therapy may have minimal side effects, as microRNAs target specific genes for regulationPersistent synthetic microRNAs can be delivered to specific brain regions to avoid off-target effects in other tissuesPatent information:Tech Ventures Reference: IR CU12162
Identifies gene expression changes that confer risk for neurodegeneration Targeted synthetic microRNAs for treatment of neurodegenerationNovel in vitro assays for drug screens that target tau expresssionNovel transgenic animals for drug screens that target tau expressionGenetic markers for Alzheimer's disease diagnosisGenetic markers for assessing an individual's risk for development of age-related tauopathy
John F. Crary, M.D., Ph.D..
美國
